bupivacaine toxicity
Recently Published Documents


TOTAL DOCUMENTS

68
(FIVE YEARS 1)

H-INDEX

14
(FIVE YEARS 0)

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 1070-1075
Author(s):  
Zhousheng Jin ◽  
Fangfang Xia ◽  
Tingting Lin ◽  
Yaoyao Cai ◽  
Hongfei Chen ◽  
...  

Abstract Objective The purpose of our study was to explore the effect of dexmedetomidine on cardiac tolerance to bupivacaine. Method Human coronary endothelial cells were used to establish in vitro model. They were randomly divided into control (Con) group, dexmedetomidine (Dex) group, bupivacaine (Bupi) group, dexmedetomidine + bupivacaine group (DB group), and dexmedetomidine + bupivacaine + PI3K inhibitor (DB-inhibitor) group. Cell activity was measured by Cell counting kit-8 (CCK-8). Transwell was used to detect cell permeability. Western blotting was used to detect the protein expression of related factors. Results There were no notable differences in cell activity among the five groups (P > 0.05). Dexmedetomidine significantly reduced the permeability of endothelial cells to bupivacaine and increased the protein expression of Zonulaoeeludens-1 (ZO-1) (P < 0.01). However, the aforementioned effects of dexmedetomidine were disappeared after the addition of PI3K inhibitors. Furthermore, Dex and DB markedly increased the protein expression of PI3K, p-Akt, and p-PTEN in comparison with Con group (P < 0.001), but there was no significant difference in p-PTEN among DB-inhibitor, Con, and Bupi groups (P > 0.05). Conclusion Dex reduced Bupi-induced vasopermeability through protein expression of ZO-1 and PI3K/Akt pathway, which may lead to the decrease of Bupi-induced cardiotoxicity.


Author(s):  
Z. Nlandu ◽  
M.I. Malik ◽  
S. Soleye ◽  
T. Osantoski ◽  
Z. Rabeeah
Keyword(s):  

2018 ◽  
Vol 4 (2) ◽  
pp. 227-231 ◽  
Author(s):  
Marc R. Angerame ◽  
Gavin P. Hart ◽  
Susan M. Odum ◽  
Bryan D. Springer

2018 ◽  
Vol 71 (11) ◽  
pp. A2141
Author(s):  
Kevin Ergle ◽  
Tripti Gupta ◽  
Jennifer Davis ◽  
Hamang Patel

2015 ◽  
Vol 5 (1_suppl) ◽  
pp. s-0035-1554233-s-0035-1554233
Author(s):  
Tomaz Velnar ◽  
Lidija Gradisnik ◽  
Gorazd Bunc

2014 ◽  
Vol 68 (2) ◽  
pp. 71-75
Author(s):  
Daniela Chaparoska ◽  
Natalija Baneva

Abstract The use of intravenous lipid emulsions (ILEs) as antidote in local anesthetic systemic toxicity has gained widespread support following convincing data from animal models, and successful case reports in humans. An injection of a simple, intravenous nutritional solution could be acutely life-saving for a patient with severe drug overdose. But dozens of published case reports support this observation, the first ones made more than a decade ago in a rodent model of bupivacaine toxicity. It is even more surprising that such a simple formulation can rapidly reverse severe clinical toxicity from a variety of vastly disparate medications with distinct pharmacodynamics and mechanisms of action. This review will focus on the clinical application of lipid emulsion therapy in resuscitation from drug-related toxicity and will provide an introduction to the development of a method, guidelines for its use, and insights into potential controversies and future applications [1].


Sign in / Sign up

Export Citation Format

Share Document